Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 1,970,000 shares, a decrease of 5.3% from the May 31st total of 2,080,000 shares. Based on an average daily volume of 185,600 shares, the days-to-cover ratio is presently 10.6 days. Currently, 9.6% of the company’s stock are short sold.

Dianthus Therapeutics Trading Down 9.0 %

NASDAQ DNTH opened at $26.27 on Wednesday. The company has a market cap of $771.02 million, a PE ratio of -4.51 and a beta of 1.88. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The stock has a 50 day moving average of $23.94 and a 200-day moving average of $21.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. As a group, sell-side analysts predict that Dianthus Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics during the 4th quarter valued at $25,000. Citigroup Inc. acquired a new stake in Dianthus Therapeutics during the 3rd quarter valued at $53,000. Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at $390,000. Hussman Strategic Advisors Inc. bought a new position in Dianthus Therapeutics during the 1st quarter worth $630,000. Finally, Laurion Capital Management LP bought a new position in Dianthus Therapeutics during the 3rd quarter worth $497,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on DNTH. Jefferies Financial Group increased their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. HC Wainwright began coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $40.00 target price for the company. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Raymond James raised their price target on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and an average price target of $42.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.